基于“短链脂肪酸-肠屏障”途径探讨中药在腹泻型肠易激综合征中的干预研究进展

doi:10.3969/j.issn.1006-5725.2024.15.023

Abstract

Abstract:

Diarrhea-predominant irritable bowel syndrome （IBS-D） is a clinically common functional gastrointestinal disease， the "SCFAs-intestinal barrier" pathway plays an important role in the pathogenesis of IBS-D. Traditional Chinese medicine monomers/compounds or Chinese medicine compound can treat IBS-D by regulating the "SCFAs-intestinal barrier" through multiple pathways and multiple targets. This article takes the relationship between SCFAs and the four major intestinal barriers， as well as the mediating effect of IBS-D，as the starting point to systematically review and sort out the relevant literature on the targeted regulation of "SCFAs-intestinal barrier" in the treatment of IBS-D by Traditional Chinese medicine monomers/compounds and Chinese medicine compound； explores the theoretical basis of IBS-D caused by "SCFAs-intestinal barrier" from the perspective of "Large intestine dominating fluid"， in order to provid ideas for Traditional Chinese medicine to establish a precision treatment system with Chinese medicine characteristics.

Key words: SCFAs-intestinal barrier, diarrhea-predominant irritable bowel syndrome, large intestine dominating fluid, traditional Chinese medicine monomers/compounds, Chinese medicine compound, research progress

CLC Number:

R574.62

Xin DOU,Changhui HE,Xiao MEI,Haidi PAN,Yuanxin MA,Wei. WANG. Research progress on the intervention of traditional Chinese medicine in IBS⁃D based on the "SCFAs⁃intestinal barrier" pathway[J]. The Journal of Practical Medicine, 2024, 40(15): 2177-2182.

Figures/Tables 2

References 49

1	OKA P， PARR H， BARBERIO B， et al. Global prevalence of irritable bowel syndrome according to Rome Ⅲ or Ⅳ criteria： a systematic review and meta-analysis［J］. Lancet Gastroenterol Hepatol， 2020， 5（10）：908-917. doi:10.1016/s2468-1253(20)30217-x doi: 10.1016/s2468-1253(20)30217-x
2	LIU J， PENG R， TAN Q， et al. Proteomic analysis of rat colonic mucosa following acupuncture treatment for irritable bowel syndrome with diarrhea［J］. PLoS One， 2022， 17（9）：e0273853. doi:10.1371/journal.pone.0273853 doi: 10.1371/journal.pone.0273853
3	SHAIDULLOV I F， SOROKINA D M， SITDIKOV F G， et al. Short chain fatty acids and colon motility in a mouse model of irritable bowel syndrome［J］. BMC Gastroenterol， 2021， 21（1）：37. doi:10.1186/s12876-021-01613-y doi: 10.1186/s12876-021-01613-y
4	YAO J P， ZHAO Y， CHEN Y， et al. Effect of electroacupuncture on intestinal epithelial mucosal barrier function in rats with diar-rhea-predominant irritable bowel syndrome［J］. Acupunct Res， 2020，45（5）：357-362.
5	ZIEGLER K， KERIMI A， POQUET L， et al. Butyric acid increases transepithelial transport of ferulic acid through upregulation of the monocarboxylate transporters slc16a1 （mct1） and slc16a3 （mct4）［J］. Arch Biochem Biophys， 2016， 599：3-12. doi:10.1016/j.abb.2016.01.018 doi: 10.1016/j.abb.2016.01.018
6	CHANG G， ZHANG H， WANG Y， et al. Microbial community shifts elicit inflammation in the caecal mucosa via the GPR41/43 signalling pathway during subacute ruminal acidosis［J］. BMC Vet Res， 2019， 15（1）：298. doi:10.1186/s12917-019-2031-5 doi: 10.1186/s12917-019-2031-5
7	WANG C M， HAN G H， MA S X. Effects of short-chain fatty acids on intestinal m-ucosal barrier［J］. Chin J Microecol， 2022，34（12）：1471-1475.
8	YAP Y A， LEOD K H MC， KENZIE C I MC， et al. An acetate-yielding diet imprints an immune and anti-microbia-l programme against enteric infection［J］. Clin Transl Immunology， 2021， 10（1）：e1233. doi:10.1002/cti2.1233 doi: 10.1002/cti2.1233
9	ZHAN K， WU H M， ZHENG H， et al. Alterations in gut microbiota-short-chain fatty acid axis in rats with diarrhea-predominant irritable bowel syndrome and the effect of sodium butyrate［J］. Chin J Comparat Med， 2023，33（9）：16-24.
10	CHONG P P， CHIN V K， LOOI C Y， et al. The Microbiome and Irritable Bowel Syndrome-A Review on the Pathophysiology， Current Research and Future Therapy［J］. Front Microbiol， 2019， 10：1136. doi:10.3389/fmicb.2019.01870 doi: 10.3389/fmicb.2019.01870
11	YANG Z Y， GONG Z P， WANG Y J， et al. Comparison of pharmacokinetics after single and multiple oral administrations of Wuji Wan in irritable bowel syndrome rats［J］. Chin J Comparat Med， 2022，32（1）：13-23.
12	SHIN A， XING Y， WASEEM M R， et al. Microbiota-Short Chain Fatty Acid Relationships and Microbial Substrate Preferences Vary Across the Spectrum of Irritable Bowel Syndrome （IBS）［J］. medRxiv， 2024：2024.01.31.24302084.
13	SUN Q H， LIU Z J， ZHANG L， et al. Sex-based differences in fecal short-chain fatty acid and gut microbiota in irritable bowel syndrome patients［J］. J Digest Dis， 2021， 22（5）：246-255. doi:10.1111/1751-2980.12988 doi: 10.1111/1751-2980.12988
14	HUANG Y F， LIU X H， WU H， et al. The relationship between intestinal mucosal barrier and intestinal microflora［J］. Chin J Microecol， 2019，31（12）：1465-1469.
15	张惠华，梁亚楠，张蕾. 短链脂肪酸的检测方法、生理作用及其与疾病的相关性研究［J］. 当代医药论丛，2019，17（15）：97-99. doi:10.3969/j.issn.2095-7629.2019.15.067 doi: 10.3969/j.issn.2095-7629.2019.15.067
16	SCHROEDER B O， BIRCHENOUGH G， STAHLMAN M，et al. Bifidobacteria or Fiber Protects against Diet-Induced Microbiota-Mediated Colonic Mucus Deterioration［J］. Cell Host Microbe， 2018， 23（1）：27-40. doi:10.1016/j.chom.2017.11.004 doi: 10.1016/j.chom.2017.11.004
17	MA S， YEOM J， LIM Y. Specific activation of hypoxia-inducible factor-2α by propionate metabolism via a β-oxidation-like pathway stimulates muc2 production in intestinal goblet cells［J］.Biomed Pharmacother， 2022， 155：113672. doi:10.1016/j.biopha.2022.113672 doi: 10.1016/j.biopha.2022.113672
18	JUNG T， HAN K， PARK J， et al. Butyrate modulates mucin secretion and bacterial adherence in lovo cells via mapk signaling［J］. PLoS One， 2022， 17（7）：e269872. doi:10.1371/journal.pone.0269872 doi: 10.1371/journal.pone.0269872
19	NYSTROM E E L， BIRCHENOUGH G M H， VAN DER POST S，et al. Calcium-activated Chloride Channel Regulator 1 （CLCA1） Controls Mucus Expansion in Colon by Proteolytic Activity［J］. EBioMedicine， 2018， 33：134-143. doi:10.1016/j.ebiom.2018.05.031 doi: 10.1016/j.ebiom.2018.05.031
20	SHAIDULLOV I F， SOROKINA D M， SITDIKOV F G， et al. Short chain fatty acids and colon motility in a mouse model of irritable bowel syndrome［J］. BMC Gastroenterol， 2021， 21（1）：37. doi:10.1186/s12876-021-01613-y doi: 10.1186/s12876-021-01613-y
21	BEISNER J， FILIPE R L， KADEN-VOLYNETS V， et al. Prebiotic Inulin and Sodium Butyrate Attenuate Obesity-Induce-d Intestinal Barrier Dysfunction by Induction of Antimicrobial Peptides［J］. Front Immunol， 2021， 12：678360. doi:10.3389/fimmu.2021.678360 doi: 10.3389/fimmu.2021.678360
22	SALERI R， BORGHETTI P， RAVANETTI F， et al. Effects of different short-chain fatty acids （scfa） on gene expression of proteins involved in barrier function in ipec-j2［J］. Porcine Health Manag， 2022， 8（1）：21. doi:10.1186/s40813-022-00264-z doi: 10.1186/s40813-022-00264-z
23	BILOTTA A J， MA C， YANG W， et al. Propionate Enhances Cell Speed and Persistence to Promote Intestinal Epithelial Turnover and Repair［J］. Cell Mol Gastroenterol Hepatol， 2021， 11（4）：1023-1044. doi:10.1016/j.jcmgh.2020.11.011 doi: 10.1016/j.jcmgh.2020.11.011
24	WANG D， LIU C D， LI H F， et al. LSD1 mediates microbial metabolite butyrate-induced thermogenesis in brown and white adipose tissue［J］. Metabolism， 2020， 102：154011. doi:10.1016/j.metabol.2019.154011 doi: 10.1016/j.metabol.2019.154011
25	代仔怡，武卫东，梁继芳，等. 短链脂肪酸平衡在脓毒症治疗中的研究进展［J］. 实用医学杂志，2022，38（3）：266-270. doi:10.3969/j.issn.1006-5725.2022.03.002 doi: 10.3969/j.issn.1006-5725.2022.03.002
26	WACLAWIKOVA B， CODUTTI A， ALIM K， et al. Gut microbiota-motility interregulation： insights from in vivo， ex vivo and in silico studies［J］. Gut Microbes， 2022， 14（1）：1997296. doi:10.1080/19490976.2021.1997296 doi: 10.1080/19490976.2021.1997296
27	BOLTE L A， VICH V A， IMHANN F， et al. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome［J］. Gut， 2021， 70（7）：1287-1298. doi:10.1136/gutjnl-2020-322670 doi: 10.1136/gutjnl-2020-322670
28	BRUNKWALL L， ERICSON U， NILSSON P M， et al. Self-reported bowel symptoms are associated with differences in overall gut microbiota composition and enrichment of Blautia in a population-based cohort［J］. J Gastroenterol Hepatol， 2021， 36（1）：174-180. doi:10.1111/jgh.15104 doi: 10.1111/jgh.15104
29	ZHEN Z， XIA L， YOU H， et al. An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhon-g Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome［J］. Front Pharmacol， 2021， 12：746923. doi:10.3389/fphar.2021.746923 doi: 10.3389/fphar.2021.746923
30	齐绍云，蔡洁毅，周龙艳，等. 防风对PI-IBS模型大鼠肠道菌群及丝氨酸蛋白酶信号的影响［J］. 中药新药与临床药理，2015，26（6）：790-796.
31	刘雪松，魏鸿雁，石磊岭，等. 骆驼刺提取物对腹泻型肠易激综合征模型大鼠水液代谢和胃肠激素水平的影响［J］. 中国新药与临床杂志，2019，38（3）：169-173.
32	GENG F， MAO Y， CONG S， et al. Protective effect of schisandrin A on intestinal mucosal barrier function in diarrhea-predominant irritable bowel syndrome rats［J］. Chin J Patho， 2022，38（7）：1266-1273.
33	BAI X， FU R， DUAN Z， et al. Ginsenoside Rk3 alleviates gut microbiota dysbiosis and colonic inflammation in antibiotic-treated mice［J］. Food Res Int， 2021， 146：110465. doi:10.1016/j.foodres.2021.110465 doi: 10.1016/j.foodres.2021.110465
34	何晗，但林蔚，王巧珍，等. 基于16S rRNA高通量测序研究麸炒前后白术水煎液及多糖对脾虚泄泻型大鼠肠道菌群的影响［J］. 中药药理与临床，2022，38（2）：136-141.
35	XIE Y， ZHAN X， TU J， et al. Atractylodes oil alleviates diarrhea-predominant irritable bowel syndrome by regul-ating intestinal inflammation and intestinal barrier via SCF/c-kit and MLCK/MLC2 pathways［J］. J Ethnopharmacol， 2021， 272：113925. doi:10.1016/j.jep.2021.113925 doi: 10.1016/j.jep.2021.113925
36	LI L， CUI H， LI T， et al. Synergistic Effect of Berberine-Based Chinese Medicine Assembled Nanostructures on Diarrhea-Predominant Irritable Bowel Syndrome In Vivo［J］. Front Pharmacol， 2020， 11：1210. doi:10.3389/fphar.2020.01210 doi: 10.3389/fphar.2020.01210
37	詹胜刚. 小檗碱对肠易激综合征大鼠肠道菌群及免疫的影响［D］. 广州：暨南大学，2017.
38	杨康，梅华迪，马现永，等. 厚朴酚对动物肠道黏膜屏障功能的影响及其调控机制［J］. 动物营养学报，2024，36（1）：74-85. doi:10.12418/CJAN2024.008 doi: 10.12418/CJAN2024.008
39	张儒奇，方志安，韩文庆，等. 葛根芩连汤对腹泻型肠易激综合征大鼠肠道菌群的影响［J］. 中国中药杂志，2022，47（24）：6709-6719.
40	ZHANG Y Z， LI Y C， YANG Y F， et al. The regulatory effect of Xiangsha Liujunzi Tang on gut microbiota and its metabolites SCFAs in IBS-D rats with spleen deficiency type［J］. Chin Trad Patent Med， 2024，46（1）：272-277.
41	胡朋，符燕，王锋. 四神丸合附子理中汤加减治疗腹泻型肠易激综合征的疗效及对肠道菌群的影响［J］. 河北中医，2023，45（9）：1472-1475. doi:10.3969/j.issn.1002-2619.2023.09.015 doi: 10.3969/j.issn.1002-2619.2023.09.015
42	尹德菲，魏秀楠，刘佳卉，等. 理肠饮治疗腹泻型肠易激综合征肝郁脾虚证的临床疗效及机制研究［J］. 南京中医药大学学报，2022，38（8）：687-695.
43	丁晓洁，孙喜灵，于晓飞，等. 乌梅丸对腹泻型肠易激综合征模型大鼠肠道菌群和炎症因子的影响［J］. 辽宁中医杂志，2019，46（6）：1296-1299+1345.
44	申中美. 参苓白术散对腹泻型肠易激综合征的临床疗效系统评价及作用机制研究［D］. 南京：南京中医药大学，2020.
45	谢慧. 肠康方联用结肠靶向益生菌对IBS-D大鼠的协同治疗作用研究［D］. 南京：南京中医药大学，2020.
46	胡蓉，李瑞. 理中汤合小建中汤加减治疗肠易激综合征疗效及对肠屏障功能、血清炎性因子和肠道菌群的影响［J］. 四川中医， 2023， 41（10）：120-123.
47	张声生，王垂杰，李玉锋，等. 泄泻中医诊疗专家共识意见（2017）［J］. 中医杂志， 2017， 58（14）：1256-1260.
48	QIU F， ZHENG C， ZHU J， et al. The Traditional Chinese Medicine Pathology and Physiology of Colorectal Cancer Based on the Theory of “Large intestine dominating fluid”［J］. Guiding J Tradit Chin Med Pharm，2018，24（1）：68-70.
49	田琳，柯晓，吴松鹰，等. 从“大肠主津”理论探讨功能性便秘与肠道微生态的相关性［J］. 世界科学技术-中医药现代化，2022，24（4）：1695-1700.

[1]	Shan GAO,Kun JI,Li ZHAO,Yujia XING,Yandong XIE,Xiqiang CAI. Research progress on esophageal squamous intraepithelial neoplasia [J]. The Journal of Practical Medicine, 2024, 40(3): 432-438.
[2]	Ganggang LU,Shenglong LI,Yongqiang ZHAO,Yunpeng JIA,Yonglin LIANG,Yuanbo. ZHAO. Research progress on the correlation between oxidative stress and ferroptosis in diabetic impotence [J]. The Journal of Practical Medicine, 2024, 40(16): 2229-2235.
[3]	Shan′gao HUANG,Yueling WU,Ying. ZHANG. Aiming for the future： The latest advances in targeted therapy for ovarian cancer [J]. The Journal of Practical Medicine, 2024, 40(14): 1901-1907.
[4]	Haixia YUAN,Xinmin HAN,Tianyi CHEN,Yuchen. SONG. Progress on structural abnormalities in the cerebral cortex in children with attention deficit/hyperactivity disorder [J]. The Journal of Practical Medicine, 2024, 40(10): 1455-1459.
[5]	Yadan CHE,Lixia. LI. Reaserch progress on small molecule anti⁃angiogenic drugs for advanced breast cancer [J]. The Journal of Practical Medicine, 2023, 39(22): 2866-2871.
[6]	LIU Hui, HE Caixian, PENG Jiyong, ZHONG Xi, LIAO Kai, YUAN Yawei, ZHENG Ronghui.. Carotid arterial injuries caused by radiotherapy for nasopharyngeal carcinoma：A review [J]. The Journal of Practical Medicine, 2023, 39(10): 1201-1205.
[7]	LI Yanwei, WANG Bin, MIAO Yulu, LI Xiao⁃ jin, ZHANG Yadong, HAN Juan, ZHUANG Pengwei, ZHANG Yanjun.. Research progress of intestinal barrier dysfunction in sepsis [J]. The Journal of Practical Medicine, 2022, 38(7): 799-803.
[8]	ZHANG Ying, WU Yueling.. Immunotherapy incervical cancer：The advent of precision medicine [J]. The Journal of Practical Medicine, 2022, 38(15): 1856-1859.
[9]	WAN Jingfang, CHEN Kehong.. Progress on preventing peritoneal fibrosis in peritoneal dialysis [J]. The Journal of Practical Medicine, 2022, 38(10): 1286-1291.
[10]	LI Liu, YU Jianhua. . Research progress on risk factors and prevention and treatment of AIDS ⁃related cardiovascular diseases [J]. The Journal of Practical Medicine, 2021, 37(20): 2687-2691.

Research progress on the intervention of traditional Chinese medicine in IBS⁃D based on the "SCFAs⁃intestinal barrier" pathway

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 49

Related Articles 10

Recommended Articles

Metrics

Comments